These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31441493)

  • 1. A new therapeutic strategy with istradefylline for postural deformities in Parkinson's disease.
    Fujioka S; Yoshida R; Nose K; Hayashi Y; Mishima T; Fukae J; Kitano K; Kikuchi H; Tsuboi Y
    Neurol Neurochir Pol; 2019; 53(4):291-295. PubMed ID: 31441493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with istradefylline for postural abnormalities in Parkinson's disease.
    Deutschländer AB
    Neurol Neurochir Pol; 2019; 53(4):239-241. PubMed ID: 31469906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of striatal & postural deformities in patients with Parkinson's disease.
    Pandey S; Kumar H
    Indian J Med Res; 2016 Nov; 144(5):682-688. PubMed ID: 28361820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of and factors associated with postural deformities in Chinese patients with multiple system atrophy.
    Zhang L; Cao B; Zou Y; Wei QQ; Ou R; Zhao B; Yang J; Wu Y; Shang H
    Parkinsonism Relat Disord; 2019 Jul; 64():324-327. PubMed ID: 30987897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Could istradefylline be a treatment option for postural abnormalities in mid-stage Parkinson's disease?
    Suzuki K; Miyamoto T; Miyamoto M; Uchiyama T; Hirata K
    J Neurol Sci; 2018 Feb; 385():131-133. PubMed ID: 29406892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of spinal cord stimulation for painful camptocormia with Pisa syndrome in Parkinson's disease: a case report.
    Akiyama H; Nukui S; Akamatu M; Hasegawa Y; Nishikido O; Inoue S
    BMC Neurol; 2017 Aug; 17(1):148. PubMed ID: 28774283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of postural deformities on neck function and pain in patients with Parkinson's disease.
    Alwardat M; Schirinzi T; Di Lazzaro G; Franco D; Imbriani P; Sinibaldi Salimei P; Mercuri NB; Pisani A
    NeuroRehabilitation; 2019; 44(1):79-84. PubMed ID: 30741700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of postural deformities on back function and pain in patients with Parkinson's disease.
    Alwardat M; Schirinzi T; Di Lazzaro G; Franco D; Sinibaldi Salimei P; Mercuri NB; Pisani A
    NeuroRehabilitation; 2019; 44(3):419-424. PubMed ID: 31177242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postural deformities in Parkinson's disease.
    Doherty KM; van de Warrenburg BP; Peralta MC; Silveira-Moriyama L; Azulay JP; Gershanik OS; Bloem BR
    Lancet Neurol; 2011 Jun; 10(6):538-49. PubMed ID: 21514890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of istradefylline for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Drug Saf; 2015 May; 14(5):769-75. PubMed ID: 25676023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of Spinal Disorders in Parkinson's Disease].
    Iwamuro H; Ohara Y; Umemura A; Hattori N; Arai H
    No Shinkei Geka; 2021 Jan; 49(1):171-184. PubMed ID: 33494064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postural Disorders and Antiparkinsonian Treatments in Parkinson Disease: An Exploratory Case-Control Study.
    Ameghino L; Bruno V; Merello M
    Clin Neuropharmacol; 2018; 41(4):123-128. PubMed ID: 29927803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
    Hauser RA; Hubble JP; Truong DD;
    Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonist-induced antecollis in Parkinson's disease.
    Uzawa A; Mori M; Kojima S; Mitsuma S; Sekiguchi Y; Kanesaka T; Kuwabara S
    Mov Disord; 2009 Dec; 24(16):2408-11. PubMed ID: 19890970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and clinical correlates of postural and striatal deformities in Parkinson's disease.
    Cervantes-Arriaga A; Rodríguez-Violante M; Morales-Briceño H; Neri-Nani G; Millán-Cepeda R; Velázquez-Osuna S
    Clin Neurol Neurosurg; 2016 Mar; 142():140-144. PubMed ID: 26866776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gait dynamics in Pisa syndrome and Camptocormia: The role of stride length and hip kinematics.
    Tramonti C; Di Martino S; Unti E; Frosini D; Bonuccelli U; Rossi B; Ceravolo R; Chisari C
    Gait Posture; 2017 Sep; 57():130-135. PubMed ID: 28623760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
    Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
    Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
    Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
    Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
    Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.